Stay updated with breaking news from Earlier Lines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.
Bristol Myers Squibb's Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan TOKYO,...
Results include a landmark study that involved seamless collaboration across adult and pediatric patient groups, leading to a highly diverse study population. Other coverage addresses access to novel therapies and what's coming in the pipeline, including CAR T-cell therapy with tyrosine kinase inhibitors.
A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.
Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.